Bicocca Open Archive

Logo unimib boa
PIAZZA, ROCCO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.596
EU - Europa 10.884
AS - Asia 4.513
SA - Sud America 371
AF - Africa 56
Continente sconosciuto - Info sul continente non disponibili 23
OC - Oceania 11
Totale 32.454
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.318
IT - Italia 2.813
DE - Germania 2.395
SG - Singapore 1.994
RU - Federazione Russa 1.500
IE - Irlanda 1.189
CN - Cina 1.163
SE - Svezia 1.111
HK - Hong Kong 621
UA - Ucraina 551
GB - Regno Unito 383
BR - Brasile 317
CA - Canada 266
FI - Finlandia 207
ID - Indonesia 206
FR - Francia 186
IN - India 135
TR - Turchia 125
VN - Vietnam 106
DK - Danimarca 103
AT - Austria 95
NL - Olanda 85
BE - Belgio 76
JP - Giappone 27
BG - Bulgaria 26
CH - Svizzera 25
ES - Italia 25
IR - Iran 24
EU - Europa 22
PL - Polonia 22
CZ - Repubblica Ceca 21
AR - Argentina 20
LT - Lituania 15
ZA - Sudafrica 15
KR - Corea 13
EG - Egitto 11
NO - Norvegia 11
PK - Pakistan 10
AZ - Azerbaigian 9
GR - Grecia 9
MA - Marocco 9
PE - Perù 9
RO - Romania 9
TH - Thailandia 8
AU - Australia 7
BD - Bangladesh 7
EC - Ecuador 7
KG - Kirghizistan 7
PH - Filippine 7
UZ - Uzbekistan 7
MX - Messico 6
TN - Tunisia 6
CO - Colombia 5
IL - Israele 5
LV - Lettonia 5
AE - Emirati Arabi Uniti 4
AM - Armenia 4
BO - Bolivia 4
CL - Cile 4
JO - Giordania 4
NZ - Nuova Zelanda 4
SA - Arabia Saudita 4
SC - Seychelles 4
VE - Venezuela 4
GE - Georgia 3
LA - Repubblica Popolare Democratica del Laos 3
LK - Sri Lanka 3
MK - Macedonia 3
MU - Mauritius 3
MY - Malesia 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
AL - Albania 2
BY - Bielorussia 2
HU - Ungheria 2
IQ - Iraq 2
KE - Kenya 2
KZ - Kazakistan 2
NP - Nepal 2
PA - Panama 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
GT - Guatemala 1
HR - Croazia 1
KW - Kuwait 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
MT - Malta 1
NG - Nigeria 1
PR - Porto Rico 1
SI - Slovenia 1
TG - Togo 1
Totale 32.451
Salva come PNG Salva come JPEG
Città #
Ann Arbor 4.898
Frankfurt am Main 1.539
Singapore 1.280
Woodbridge 1.224
Dublin 1.160
Chandler 1.067
Milan 1.032
Fairfield 965
Ashburn 788
Wilmington 742
Houston 732
Hong Kong 608
Jacksonville 527
Dearborn 507
New York 433
Seattle 399
Santa Clara 369
Cambridge 307
Princeton 302
Shanghai 220
Göttingen 205
Jakarta 200
Nanjing 163
Beijing 144
Altamura 142
Lawrence 120
Boardman 99
Moscow 98
Helsinki 91
Toronto 89
Lachine 85
San Diego 78
Guangzhou 76
Brussels 72
Nuremberg 72
Fürstenwalde 71
Los Angeles 70
Rome 67
Romola 63
Munich 62
Fremont 58
Monza 58
Council Bluffs 57
Dong Ket 57
Andover 54
Nanchang 53
Ottawa 52
Vienna 51
Shenyang 50
Lissone 49
Kocaeli 46
Tianjin 42
Hebei 41
London 40
Assago 38
Düsseldorf 35
Jiaxing 33
Turin 33
Carate Brianza 31
Chicago 30
Jinan 30
Falls Church 29
Como 28
Kunming 28
Norwalk 26
Pune 26
Sacramento 25
Hangzhou 24
Lauterbourg 24
Changsha 23
São Paulo 23
Plovdiv 22
Sesto San Giovanni 22
Desio 21
Huizen 21
Redmond 21
Edmonton 20
Genoa 20
Lodz 20
Pavia 20
Washington 20
Dallas 18
Lappeenranta 18
Bari 17
Mountain View 17
Florence 16
Seregno 16
Buffalo 15
Hefei 15
Kiev 15
Bergamo 14
Bonndorf 14
Brescia 14
The Dalles 13
Bologna 12
Cinisello Balsamo 12
Leawood 12
Meda 12
Ningbo 12
Nürnberg 12
Totale 22.841
Salva come PNG Salva come JPEG
Nome #
Longitudinal cancer evolution from single cells 485
Personalized therapy design for liquid tumors via optimal control theory 458
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations 437
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 425
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 381
A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data 378
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 372
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 333
An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments 331
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 326
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 324
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 320
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 317
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 307
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis 301
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 301
A computational procedure to identify and annotate somatic mutations in next-generation sequencing data 289
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 289
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 288
WHOLE-EXOME SEQUENCING OF A PHILADELPHIA NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENT THROUGH THE EXON-CAPTURE TECHNIQUE 286
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 284
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 283
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 281
Chronic myeloid leukemia: Second-line drugs of choice 278
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 278
Imatinib long term effects study: three years of follow-up and assessment 277
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 276
LACE: Inference of cancer evolution models from longitudinal single-cell sequencing data 267
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 265
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 259
Variant calling from scRNA-seq data allows the assessment of cellular identity in patient-derived cell lines 252
VirMutSig: Discovery and assignment of viral mutational signatures from sequencing data 250
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 245
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 242
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 240
Hif1a: A putative modifier of hemochromatosis 237
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 234
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 231
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 230
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 230
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 228
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 226
Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency 226
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 222
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 221
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 220
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 220
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 220
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 217
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution 216
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 212
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients 210
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 210
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 209
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 208
Human chromosome 18 and acrocentrics: A dangerous liaison 207
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 206
Reply to P. Laneuville et al 204
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation 204
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 201
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias 199
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 199
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 197
EXT 1 gene mutation induces chondrocyte cytoskeletal abnormalities and defective collagen expression in the exostoses 194
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 193
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 193
Whole-Exome Sequencing Data - Identifying Somatic Mutations 193
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 191
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 191
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 190
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 190
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 187
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 182
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 180
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 177
Mutational signatures and heterogeneous host response revealed via large-scale characterization of SARS-CoV-2 genomic diversity 177
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS 175
ABL INHIBITOR BMS354825 BINDING MODE IN ABELSON KINASE REVEALED BY MOLECULAR DOCKING STUDIES 175
Epigenetic Silencing of the Pro-Apoptotic Bim Gene in Glucocorticoid Poor-Responsive Pediatric Acute Lymphoblastic Leukemia, and Its Reversal by Histone Deacetylase Inhibition 175
Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis 175
The role of bosutinib in the treatment of chronic myeloid leukemia 175
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years 174
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 174
Identification of a Novel Splicing Mutation in Blast Crisis Transformation of Chronic Myeloid Leukemia Integrating Whole-exome and RNA-Seq data 173
First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis 173
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 171
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 171
Whole-Exome Sequencing of 8 Atypical Chronic Myeloid Leukaemia Patients 171
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 169
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 167
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 165
Autoimmune hepatitis presenting as imatinib toxicity: description of a case and of therapeutic alternatives 164
Read-through transcripts in normal human lung parenchyma are down-regulated in lung adenocarcinoma 162
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 162
Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage 161
Identification of Novel Point Mutations in Splicing Sites by the Integration of Exome and RNA Sequencing Data in Myeloproliferative Diseases 159
NPM/ALK binds and phosphorylates the RNA/DNA binding protein PSF in anaplastic large cell lymphoma 158
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR) 157
Whole-exome sequencing of matched chronic phase and blast crisis CML samples to reveal mechanisms of blast crisis transformation 157
How I treat newly diagnosed chronic myeloid leukemia in 2015 157
Totale 23.427
Salva come PNG Salva come JPEG
Categoria #
all - tutte 120.592
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 120.592
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020726 0 0 0 0 0 0 0 0 0 330 288 108
2020/20214.809 192 177 451 460 419 455 513 448 453 463 342 436
2021/20223.341 313 301 354 244 233 295 225 183 183 227 295 488
2022/20235.119 604 1.360 515 520 400 631 90 242 313 100 183 161
2023/20244.287 162 187 223 260 506 1.076 753 151 308 145 97 419
2024/20257.231 486 867 610 551 843 425 673 370 875 1.531 0 0
Totale 33.672